Articaine vs Dexmedetomidine Supplemented Articaine

Ain Shams University

Status and phase: Completed; Early Phase 1

Conditions: Renal Failure

Treatments: Drug: Articaine; Drug: Dexmedetomidine

Study type: Interventional

Funder types: Other

Identifiers

NCT04171349

Articaine

Details and patient eligibility

About

The aim of this study to test efficacy of adding dexmedetomidine to articaine on sensory, motor and duration of analgesia during hemodialysis fistula creation under ultrasound guided supraclavicular block

Full description

Adult fifty patient with chronic renal failure on hemodialysis, scheduled for arteriovenous fistula creation under ultrasound guided supraclavicular block. Patients were randomly allocated in two group. The articaine group (group A) received 40 ml articaine hydrochloride 2% and articaine-dexmedetomidine group (group AD) received 40 ml. Of articaine 2% mixed with dexmedetomidine (1micogram/kg)

Enrollment: 50 patients

Sex: All

Ages: 25 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• adult patient with chronic renal failure on hemodialysis scheduled for radiocephalic fistula creation

Exclusion criteria

• Allergy to local anesthetics.
• Infection at the site of needle insertion.
• Those having international normalized ratio more than 1.5.
• Coagulopathy.
• Neuromuscular, or severe hepatic or severe pulmonary disease.
• Those having epilepsy.
• Patients who refused to participate.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

50 participants in 2 patient groups

Group A

Active Comparator group

Description:

Patients received ultrasound guided supraclavicular block with 40 ml of Articaine hydrochloride 2%

Treatment:

Drug: Articaine

Group AD

Experimental group

Description:

Patients received ultrasound guided supraclavicular block with 40 ml articaine 2% mixed with dexmedetomidine (1 µg/kg).

Treatment:

Drug: Articaine

Drug: Dexmedetomidine